LeMaitre Vascular, Inc. $LMAT Shares Acquired by CPC Advisors LLC

CPC Advisors LLC increased its position in shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT) by 92.1% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 19,386 shares of the medical instruments supplier’s stock after acquiring an additional 9,293 shares during the quarter. CPC Advisors LLC’s holdings in LeMaitre Vascular were worth $1,696,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the company. First Trust Advisors LP raised its position in LeMaitre Vascular by 52.7% in the second quarter. First Trust Advisors LP now owns 612,028 shares of the medical instruments supplier’s stock valued at $50,829,000 after purchasing an additional 211,280 shares during the period. Envestnet Asset Management Inc. increased its position in shares of LeMaitre Vascular by 6.8% during the 2nd quarter. Envestnet Asset Management Inc. now owns 304,556 shares of the medical instruments supplier’s stock worth $25,293,000 after purchasing an additional 19,447 shares during the last quarter. Congress Asset Management Co. raised its holdings in LeMaitre Vascular by 4.6% in the 2nd quarter. Congress Asset Management Co. now owns 673,968 shares of the medical instruments supplier’s stock valued at $55,973,000 after buying an additional 29,553 shares during the period. Public Employees Retirement System of Ohio acquired a new position in LeMaitre Vascular in the second quarter valued at about $892,000. Finally, American Century Companies Inc. lifted its position in LeMaitre Vascular by 233.0% in the second quarter. American Century Companies Inc. now owns 34,008 shares of the medical instruments supplier’s stock valued at $2,824,000 after buying an additional 23,794 shares during the last quarter. 84.64% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of brokerages have weighed in on LMAT. Barrington Research reiterated an “outperform” rating and set a $95.00 price target on shares of LeMaitre Vascular in a research report on Wednesday, October 15th. Cantor Fitzgerald reiterated a “neutral” rating and issued a $95.00 target price on shares of LeMaitre Vascular in a report on Monday, November 10th. Roth Capital restated a “buy” rating and set a $108.00 price target on shares of LeMaitre Vascular in a research note on Wednesday, November 5th. Weiss Ratings reaffirmed a “buy (b-)” rating on shares of LeMaitre Vascular in a research note on Monday, December 29th. Finally, Wall Street Zen downgraded LeMaitre Vascular from a “buy” rating to a “hold” rating in a report on Saturday, December 6th. Four equities research analysts have rated the stock with a Buy rating and four have given a Hold rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $100.20.

LeMaitre Vascular Stock Performance

Shares of LMAT stock opened at $83.83 on Tuesday. The firm has a 50 day moving average of $84.70 and a two-hundred day moving average of $87.34. The stock has a market capitalization of $1.90 billion, a PE ratio of 36.13, a P/E/G ratio of 1.89 and a beta of 0.68. The company has a quick ratio of 11.45, a current ratio of 13.58 and a debt-to-equity ratio of 0.44. LeMaitre Vascular, Inc. has a 52 week low of $71.42 and a 52 week high of $105.55.

LeMaitre Vascular (NASDAQ:LMAT) last posted its quarterly earnings data on Thursday, November 6th. The medical instruments supplier reported $0.62 earnings per share for the quarter, topping analysts’ consensus estimates of $0.57 by $0.05. The business had revenue of $61.05 million for the quarter, compared to analyst estimates of $62.18 million. LeMaitre Vascular had a return on equity of 14.06% and a net margin of 22.14%.The company’s revenue was up 11.4% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.49 earnings per share. LeMaitre Vascular has set its FY 2025 guidance at 2.480-2.530 EPS and its Q4 2025 guidance at 0.640-0.690 EPS. On average, research analysts predict that LeMaitre Vascular, Inc. will post 1.94 EPS for the current fiscal year.

LeMaitre Vascular Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Thursday, December 4th. Shareholders of record on Thursday, November 20th were given a $0.20 dividend. The ex-dividend date of this dividend was Thursday, November 20th. This represents a $0.80 dividend on an annualized basis and a yield of 1.0%. LeMaitre Vascular’s dividend payout ratio (DPR) is currently 34.48%.

LeMaitre Vascular Profile

LeMaitre Vascular, Inc is a specialty medical device company focused on the development, manufacture and marketing of products for the treatment of peripheral vascular disease. Headquartered in Burlington, Massachusetts, the company’s offerings include a broad portfolio of vascular surgical instruments, grafts, patches, catheters and embolic protection devices. LeMaitre’s product lines address key areas such as arterial reconstruction, endovascular repair and vascular access, serving the needs of cardiovascular surgeons and interventional specialists.

Founded in 1983 by George D.